Can you take BPC-157 + TB-500 Stack and Larazotide together?

There is no specific, well-documented interaction rule for combining BPC-157 + TB-500 Stack and Larazotide in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, BPC-157 + TB-500 Stack or Larazotide?

BPC-157 + TB-500 Stack is currently research-stage and Larazotide is fda-approved. "Better researched" depends on your research goal — review each profile's cited sources.

Healing & Recovery · Comparison

BPC-157 + TB-500 Stack vs Larazotide

Q: What is the difference between BPC-157 + TB-500 Stack and Larazotide?

BPC-157 + TB-500 Stack: The most widely researched peptide stack for tissue repair, combining BPC-157 (angiogenesis and growth factor upregulation) with TB-500 (actin regulation and cell migration). The two compounds address complementary and non-overlapping stages of the healing cascade, producing synergistic effects in tendon, ligament, muscle, and gut injury research models. Larazotide: Larazotide (AT-1001) is a synthetic octapeptide that acts as a tight junction regulator — it competitively blocks zonulin, the primary physiological driver of intestinal permeability ('leaky gut'). It is one of the few compounds studied in human clinical trials specifically for tight junction dysfunction, with Phase 2 data in celiac disease demonstrating reduced intestinal permeability and symptom improvement even in the presence of ongoing gluten exposure. Both are in the Healing & Recovery category but differ in mechanism, dosing, and research evidence — see the full comparison.

A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

BPC-157 + TB-500 Stack

Research-stage

The most widely researched peptide stack for tissue repair, combining BPC-157 (angiogenesis and growth factor upregulation) with TB-500 (actin regulation and cell migration). The two compounds address complementary and non-overlapping stages of the healing cascade, producing synergistic effects in tendon, ligament, muscle, and gut injury research models.

Full profile

Larazotide

FDA-approved

Larazotide (AT-1001) is a synthetic octapeptide that acts as a tight junction regulator — it competitively blocks zonulin, the primary physiological driver of intestinal permeability ('leaky gut'). It is one of the few compounds studied in human clinical trials specifically for tight junction dysfunction, with Phase 2 data in celiac disease demonstrating reduced intestinal permeability and symptom improvement even in the presence of ongoing gluten exposure.

Full profile

	BPC-157 + TB-500 Stack	Larazotide
Category	Healing & Recovery	Healing & Recovery
Also known as	Wolverine Stack, BPC TB500 combination, healing stack, BPC-157 TB-500	Larazotide acetate, AT-1001, INN-202
Evidence	Research-stage	FDA-approved
Dosing range	BPC-157 250mcg + TB-500 2.5mg–BPC-157 750mcg + TB-500 7.5mg varies by component, 2–3x per week	0.25mg–1mg mg, 3x daily (before meals)
Administration	Subcutaneous injection, Intramuscular injection	Oral (capsule), Subcutaneous injection (research use)
Key side effects	BPC-157: nausea (rare), dizziness, lightheadedness, TB-500: fatigue, headache, injection site reactions, No documented combination-specific adverse effects, Theoretical oncological considerations (angiogenesis stimulation) — relevant in cancer history	Headache (most commonly reported adverse event in trials), Nausea (mild), Generally well-tolerated — adverse event rate similar to placebo in clinical trials
Cited sources	2 references	3 references

Key differences

Evidence level differs: BPC-157 + TB-500 Stack is research-stage, while Larazotide is fda-approved.
Administration: BPC-157 + TB-500 Stack — Subcutaneous injection, Intramuscular injection; Larazotide — Oral (capsule), Subcutaneous injection (research use).
Dosing units differ: BPC-157 + TB-500 Stack is dosed in varies by component, Larazotide in mg — they operate at different scales.
Frequency: BPC-157 + TB-500 Stack is typically 2–3x per week; Larazotide is 3x daily (before meals).
Research depth: this profile cites 2 sources for BPC-157 + TB-500 Stack vs 3 for Larazotide.

How each works

BPC-157 + TB-500 Stack

BPC-157 and TB-500 work through entirely non-overlapping mechanisms and have been combined in numerous community protocols for injury recovery. BPC-157 drives angiogenesis and growth factor receptor expression; TB-500 regulates actin polymerization and cell migration into the injury site. No documented negative interactions exist — the combination is considered synergistic in the healing research community based on the complementary biology of each compound.

Larazotide

Zonulin upregulation disrupts the tight junction proteins occludin and claudin, allowing paracellular passage of antigens, LPS, and inflammatory triggers into systemic circulation. Larazotide acts as a tight junction agonist by competitively displacing zonulin from its receptor and directly stabilizing tight junction complexes. The Phase 2b CeD trial (N=342) showed larazotide reduced the ratio of lactulose/mannitol (L/M ratio, standard intestinal permeability marker) and improved GI symptom scores versus placebo in actively-challenged celiac patients.

Read the full BPC-157 + TB-500 Stack profile Read the full Larazotide profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.